China Unveils Elderly Nursing Plan to Boost 90% Nurse Coverage by 2027
China’s National Health Commission (NHC), National Healthcare Security Administration (NHSA), National Administration of Traditional Chinese...
Fineline Cube
Amgen’s Uplizna Scores Third FDA Indication in Myasthenia Gravis
Amgen Inc. (NASDAQ: AMGN) announced that the U.S. FDA approved Uplizna (inebilizumab-cdon) for adult patients...
Huadao Submits China CAR‑T Application for Refractory Lymphoma in $1B Market
Suzhou Huadao Biological Pharmacy Co., Ltd. officially submitted a Marketing Authorization Application (MAA) to the...
Peijia Medical Wins NMPA Approval for TaurusTrio TAV, First Transfemoral System for Aortic Regurgitation
Peijia Medical Limited (HKG: 9996) announced that China’s National Medical Products Administration (NMPA) approved the...
Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal
Hasten Biopharmaceutical Co., Ltd. and Everest Medicines Limited (HKG: 1952) announced two strategic agreements: a...
Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial
Eli Lilly & Co. (NYSE: LLY) announced positive topline results from the Phase 3 TRIUMPH‑4...
Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment
Joincare Pharmaceutical Group Industry Co., Ltd. (SHA: 600380) announced that its Class 1 innovative drug, Pixavir...
InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program
InduPro Therapeutics, a biotechnology company defining membrane protein spatial relationships for novel therapeutics, announced a...
InnoCare’s Zurletrectinib Wins NMPA Nod as China’s First Next-Gen TRK Inhibitor
InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that its self‑developed next‑generation TRK inhibitor, Zurletrectinib...
Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery
Brii Biosciences Limited (HKG: 2137) announced a collaboration with OpenBench to leverage its structure‑driven Artificial...
GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs
UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) has initiated a breakup with Ideaya Biosciences (NASDAQ:...
B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline
B&K Corporation Limited (HKG: 2396) officially listed on the Hong Kong Stock Exchange today, offering...
OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform
Oxford BioTherapeutics (OBT), a clinical‑stage oncology company, announced a multi‑year, multi‑target strategic collaboration with GSK...
Lilly to Invest Over $6 Billion in Alabama GLP‑1 Manufacturing Hub for Orforglipron
Eli Lilly & Co. (NYSE: LLY) announced plans to invest more than USD 6 billion in a...
Sino Biopharm’s Culmerciclib Wins NMPA Approval as First CDK2/4/6 Inhibitor for Breast Cancer
Sino Biopharmaceutical (HKG: 1177) announced that Culmerciclib Capsules, the world’s first CDK2/4/6 inhibitor, received marketing...
Insilico Licenses AI‑Designed ISM4808 PHD Inhibitor to TaiGen in Two‑Digit Million Dollar Greater China Deal
Insilico Medicine and TaiGen Biotechnology (including its Beijing subsidiary TaiGen Biopharmaceuticals) announced an exclusive pipeline...
Lobemilast (Y‑3) NDA Accepted by NMPA as First Multi‑Target Stroke Neuroprotectant
Neurodawn Pharmaceutical Co., Ltd. announced that its self‑developed Category 1 chemical drug, Y‑3 for Injection (generic...
Bleecker Bio (Formation) Licenses Lynk’s CNS‑Penetrant TYK2 Inhibitor LNK01006 in $605 M Deal
Lynk Pharmaceuticals Co., Ltd. and Formation Bio announced that Bleecker Bio, a newly formed Formation...
Shanghai Pharma’s SPH3127 Renin Inhibitor Wins NMPA Approval for Primary Hypertension
Shanghai Pharmaceuticals Holding Co., Ltd. (SHA: 601607) announced that the National Medical Products Administration (NMPA)...
Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo‑Free TIL Therapy for Solid Tumors
Shanghai Juncell Therapeutics Co., Ltd. (“JunCell Biologics”) released its prospectus, announcing its intention to list...